Common Causes of Postmenopausal Bleeding in Korean Women: 10-Year Outcomes from a Single Medical Center

Min Young Kim,1,2 Yeon Soo Jung,3 Seung Joo Chon,4 Bo Hyon Yun,1,2 SiHyun Cho,1,2 Young Sik Choi,1,2 Byung Seok Lee,2,3 and Seok Kyo Seo1,2

1Department of Obstetrics and Gynecology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; 2Institute of Women’s Life Medical Science, Yonsei University College of Medicine, Seoul, Korea; 3Department of Obstetrics and Gynecology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea; 4Department of Obstetrics and Gynecology, Gil Hospital, Gachon University College of Medicine, Incheon, Korea; 2Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Received: 12 October 2016
Accepted: 30 January 2017

Address for Correspondence:
Seok Kyo Seo, MD, PhD
Department of Obstetrics and Gynecology, Severance Hospital, Institute of Women’s Life Medical Science, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
E-mail: tudolenko@yuhs.ac

INTRODUCTION

Postmenopausal bleeding (PMB) is a common medical problem with a prevalence rate as high as 10% in the general population (1,2). It is important to evaluate the cause of PMB because of its association with gynecologic malignancies (2-6). Early diagnosis may help improve survival rates, hence several diagnostic tools such as transvaginal ultrasonography or hysteroscopy have been implemented for early and accurate detection of malignancy (1,4,7-10). Recently, cancer prevalence rates have been changing due to better cancer screening modalities and health insurance coverage. Especially, cervical cancer incidence has been steadily decreasing, whereas that of endometrial cancer has been modestly increasing worldwide according to recent statistics (11-14). These changes in cancer incidence rates may also affect the number of patients per cause of PMB.

The common causes of PMB according to the data from the West are vaginal or endometrial atrophy, hormone replacement therapy (HRT), endometrial cancer, endometrial or cervical polyps, endometrial hyperplasia, and other miscellaneous diseases (15,16). However, data on causes of PMB in Asia are lacking. Therefore, we conducted a retrospective study to assess whether the causes of PMB in Korean postmenopausal women are similar to that already known.

MATERIALS AND METHODS

Women who were at least 45 years old and stopped menstruating for more than 12 months were defined as postmenopausal. Hospital database searching was done using the keyword “postmenopausal bleeding” or “vaginal bleeding” in the diagnosis. Total of 1,769 women were selected initially, and after excluding those with the exclusion criteria as mentioned below, a total of 792 postmenopausal patients who attended Yonsei University Health System, Seoul, Korea with vaginal bleeding as the chief complaint were enrolled in this study. Retrospective evaluation of the 10-year medical records (March 2005 to December 2014) of the study population was conducted. The data were arranged into the following categories: history, diagnosis, method used for confirmation of diagnosis, sonographic data, and previously prescribed medication. Since a single patient may have several diagnoses, total number of cases exceeded the number of pa-
patients. Therefore, total of 897 diagnoses were counted. All data were entered into an Excel database (Microsoft, Seattle, WA, USA) for analysis.

The exclusion criteria were as follows: unidentified pathology, no specific diagnosis, and trauma (i.e. previous large loop excision of the transformation zone [LLETZ] status, biopsy status, etc.). Patients with other medical conditions such as Behçet’s disease or pancytopenia were also excluded. The most commonly known etiology for PMB, vaginal or endometrial atrophy, was defined by sonographic data as an endometrial thickness of less than 5 mm, and by the histopathological results from biopsy or Pap smear.

The study population was divided into 2 groups: patients who visited our hospital during the first 5 years (2005–2009) and those who came during the latter 5 years (2010–2014). The 2 groups’ PMB causes were statistically compared using Pearson’s χ² test. Statistical analysis was conducted with SPSS software ver.20 (IBM, Armonk, NY, USA). Statistical significance was set at P < 0.05.

**Ethics statement**

This study was conducted according to the tenants of the Declaration of Helsinki and was approved by the Institutional Review Board at Yonsei University Health System, Severance Hospital (4-2015-1005). Written informed consent was waived due to the study’s retrospective nature and because the study data did not include any personal identifying information.

**RESULTS**

The most common cause of PMB in Korean women was vaginal or endometrial atrophy (51.1%). Endometrial and cervical polyps were the second common cause (11.5%). HRT was also on the second rank (11.5%), followed by anticoagulant medications (7.0%), cervical cancer (6.9%), endometrial cancer (5.7%), and other miscellaneous causes (Table 1). Although there were many tibolone users in the HRT group, the most common HRT medication that induced PMB was the combined estrogen and progesterone derivatives (EPT). For the anticoagulant medication group, aspirin was the most common medication followed by coumadin.

Out of the 792 patients included in the study population, 402 patients were allocated to the first 5-year group and 390 patients to the latter group. The mean age was slightly older in the latter 5-year group (62.1 ± 9.16 vs. 61.9 ± 9.26 years). The 3 most common causes were similar between the first and second halves of the decade. However, the percentage of cervical cancer decreased significantly during the second half of the decade (5.2% vs. 8.7%; P = 0.048). In addition, the percentage of endometrial cancer also decreased in the latter group but without significance (5.4% vs. 6.0%). Although no significant change in percentage was noted for HRT, its rank was higher during the latter half of the decade (2nd vs. 3rd). Most of the HRT included continuous progesterone treatment. The cyclic progesterone treatment was used by only 6 patients (12.5% of HRT users) during the first half decade, and only 5 patients (9.1% of HRT users) in the latter half. Furthermore, there were more anticoagulant users in the latter group (9.0% vs. 5.1%; P = 0.023).

**DISCUSSION**

This study evaluated the common causes of PMB among Korean postmenopausal women and apparently, has shown different results compared to the previously known causes from Caucasians and other ethnicities. The leading cause of PMB was vaginal or endometrial atrophy, but all the other causes were differently ranked. Endometrial and cervical polyps were more prevalent and endometrial cancer was relatively rare. Although requiring further studies, a report from Hong Kong (3) showed that the prevalence of endometrial cancer among women with PMB in Hong Kong was 3.8%, which is much lower than the previously reported 10% in developed countries (17). This is one representative example which depicts the possibility that endometrial cancer prevalence rate may be quite different in the Asian population.

The incidence of endometrial cancer in Korea is increasing according to previous research (Fig. 1) (12,13). However, this

**Table 1. Etiology of PMB during 2005–2009 and 2010–2014**

| Diseases        | No. (%) of cases | P value* | OR (95% CI) |
|-----------------|------------------|---------|-------------|
|                 | 2005–2009        | 2010–2014 | Total       |             |
| Atrophy         | 231 (51.2)       | 227 (51.1) | 458 (51.1) | 0.658       | 0.942 (0.724–1.226) |
| Polyp           | 54 (12.0)        | 49 (11.9)  | 103 (11.5) | 0.643       | 0.907 (0.602–1.369) |
| HRT             | 48 (10.6)        | 55 (12.3)  | 103 (11.5) | 0.428       | 1.181 (0.783–1.782) |
| Cervical cancer | 39 (8.7)         | 23 (5.2)   | 62 (6.9)   | 0.048       | 0.574 (0.337–0.979) |
| Endometrial cancer | 27 (6.0)       | 24 (5.4)   | 51 (5.7)   | 0.695       | 0.893 (0.507–1.573) |
| Anticoagulant usage | 23 (5.1)     | 40 (9.0)   | 63 (7.0)   | 0.023       | 1.833 (1.079–3.117) |
| Others          | 29 (6.4)         | 28 (6.3)   | 57 (6.4)   | 0.926       | 0.975 (0.570–1.667) |
| Total           | 451              | 446       | 897        |             |               |

PMB = postmenopausal bleeding, HRT = hormone replacement therapy, OR = odds ratio, CI = confidence interval.

*P value: Pearson χ² test.
The study demonstrated that the incidence of PMB caused by endometrial cancer did not show significant change. As indicated by cancer statistics in Korea (1993–2012) (12), although the incidence rate increased, the actual number is not substantially high. This may explain why there is some disparity between this study and the previous ones.

Among the endometrial cancer patients in the study population, the average endometrial thickness (ET) including the mass size measured by gynecologic sonography was 48 mm. Sixty-six percent of patients were shown to have an endometrial mass and 78.7% had ET more than 10 mm (Fig. 2). The percentages of patients with ET ≥ 5 mm and < 10 mm, and < 5 mm were 8.5% and 12.8%, respectively. Various reports debated the most sensitive cut-off value for ET to detect endometrial cancer by sonography. An optimal cut-off of 5 mm is being proposed (4,18) and our data clearly exceeds this limit. Hysteroscopy also aids the diagnosis, allowing visual confirmation and endometrial biopsy during the procedure, evidently increasing the screening sensitivity (7,8,10,18). For patients without PMB, the 5 mm cut-off could be recommended as described from previous studies (4,18). However, since this study result reveals that certain number of patients with ET less than 5 mm were also found to have cancer, biopsy can be considered even in patients with ET < 5 mm when PMB coexists. Further prospective studies will be needed to confirm this.

Another notable change that appeared from our results is the decreased incidence in cervical cancer over the years. According to several studies (11,12,14,19), both incidence and mortality rates of cervical cancer in Korea have been declining. In countries where organized cytological screening has been implemented, such as the US and Korea, this trend has been kept steady (Fig. 1). Due to the national cervical cancer screening program and the nation’s improved socioeconomic status, early diagnosis allowed early treatment, which helped decrease cervical cancer mortality. Additionally, human papilloma virus (HPV) vaccination was introduced into clinical practice in Korea in 2007, which will further help reducing cervical cancer incidence. Despite the decreasing trend, Korean age-standardized cervical cancer incidence is still higher than the age-standardized incidence of the world population, which may explain why cervical cancer was ranked higher in the list of Korean PMB causes. Park et al. (11) explained this by the relatively higher proportion of the elderly in the Korean population compared to the demographics of the world population.

Last, HRT usage was shown to have increasing trend in the latter 5-year group. Previous data (20,21) described decreased number of HRT users in the post-Women’s Health Initiative (WHI) era, however recently in Korea, the number seems to increase again with the rising number of tibolone users (Fig. 3). According to the Long-Term Intervention on Fractures with Tibolone (LIFT) study (22), invasive breast cancer risk was decreased by...
using tibolone. It was also shown to be as effective as EPT for postmenopausal symptoms but without causing as much PMB (20,21,23), therefore eventually the number of tibolone users continued to increase. From this study population, the latter 5-year period included more number of tibolone users than the first half of the decade (23.6% vs. 18.8%), which also reflects this phenomenon. However, as described elsewhere in literature (23), EPT is still the most common HRT-related cause of PMB and this study population also comprises more of EPT users than tibolone. This also may be the reason that the prevalence of PMB associated with HRT seems to be stationary although the number of women using HRT was previously decreased.

The limitation of this study is that the study population was recruited from a single tertiary medical center. Selection bias may be present in this study population since cancer patients are mostly converged to tertiary centers to get appropriate medical care. However, the percentage of gynecologic malignancy patients was not high enough to make significant difference in the high ranking causes of PMB. It would be reasonable to simply refer to the decreasing prevalence trend over the years. Another limitation is that the comparisons between initial and latter ‘5-year’ groups may be too short of a duration to investigate the change of cancer prevalence. Further studies with longer follow-ups will be needed to make definite conclusions.

Meanwhile, the strength of this study is that it was the first to evaluate the causes of PMB in an Asian population. Given the different ethnic background, the genetic susceptibility to certain diseases differs among populations. This study clearly revealed different etiologies of PMB in Korean women compared to the previous data. Further studies including other Asian nationalities will be needed to confirm our results.

In conclusion, only the most common cause of PMB was the same as in previous data, while other causes were all ranked differently in Korean postmenopausal women. Interestingly, cervical cancer was noted as the fourth common cause of PMB, showing greater percentage than the previous western data. The percentage of cervical cancer decreased during the latter half of the decade, reflecting the changes in the nation’s cancer prevalence rate. Additionally, the use of HRT increased.

**DISCLOSURE**

The authors have no potential conflicts of interest to disclose.

**AUTHOR CONTRIBUTION**

Conceptualization: Cho S, Lee BS, Seo SK. Data curation: Chon SJ, Yun BH. Formal analysis: Chon SJ, Seo SK. Investigation: Kim MK, Jung YS. Writing - original draft: Kim MK, Choi YS. Writing - review & editing: Lee BS, Seo SK.

**ORCID**

Min Kyoung Kim http://orcid.org/0000-0002-1753-2674

Yeon Soo Jung http://orcid.org/0000-0001-8371-3521

Seung Joo Chon http://orcid.org/0000-0003-3977-8568

Bo Hyon Yun http://orcid.org/0000-0001-5703-797X

SiHyun Cho http://orcid.org/0000-0003-2718-6645

Young Sik Choi http://orcid.org/0000-0002-1157-4822

Byung Seok Lee http://orcid.org/0000-0002-4669-8892

Seok Kyo Seo http://orcid.org/0000-0003-3404-0484

**REFERENCES**

1. Breijer MC, Mol BW. Transvaginal ultrasound measurement of the endometrium remains the first line test for investigating postmenopausal bleeding but integration of patient characteristics into testing may further improve diagnostic algorithms. *BJOG* 2016; 123: 447.

2. Salman MC, Bozdag G, Dogan S, Yuce K. Role of postmenopausal bleeding pattern and women’s age in the prediction of endometrial cancer. *Aust N Z J Obstet Gynaecol* 2013; 53: 484-8.

3. Wong AS, Lao TT, Cheung CW, Yeung SW, Fan HL, Ng PS, Yuen PM, Sahota DS. Reappraisal of endometrial thickness for the detection of endometrial cancer in postmenopausal bleeding: a retrospective cohort study. *BJOG* 2016; 123: 439-46.

4. Dueholm M, Marinovskij E, Hansen ES, Møller C, Ørtoft G. Diagnostic methods for fast-track identification of endometrial cancer in women with postmenopausal bleeding and endometrial thickness greater than 5 mm. *Menopause* 2015; 22: 616-26.

5. Smith PP, O’Connor S, Gupta J, Clark TJ. Recurrent postmenopausal bleeding: a prospective cohort study. *J Minim Invasive Gynecol* 2014; 21: 799-803.

6. Izbetgovic S, Stojkanovic G, Ribic N, Mehmedbasic E. Features of postmenopausal uterine haemorrhage. *Med Arch* 2013; 67: 431-4.

7. Loiacono RM, Trojano G, Del Gaudio N, Kardhashi A, Deliso MA, Falco G, Sforza R, Laera AF, Galise I, Trojano V. Hysteroscopy as a valid tool for
endometrial pathology in patients with postmenopausal bleeding or asymptomatic patients with a thickened endometrium: hysteroscopic and histological results. *Gynecol Obstet Invest* 2015; 79: 210-6.

8. Dueholm M, Hjorth IM, Secher P, Jørgensen A, Ørtoft G. Structured hysteroscopic evaluation of endometrium in women with postmenopausal bleeding. *J Minim Invasive Gynecol* 2015; 22: 1215-24.

9. Breijer MC, van Haneveld N, Visser NC, Verheijen RH, Mol BW, Pijnenborg IM, Opmeer BC, Timmermans A. Does probability guided hysteroscopy reduce costs in women investigated for postmenopausal bleeding? *Scientific World Journal* 2015; 2015: 605312.

10. Cavkaytar S, Kokanali MK, Ceran U, Topcu HO, Sirvan L, Doganay M. Roles of sonography and hysteroscopy in the detection of premalignant and malignant polyps in women presenting with postmenopausal bleeding and thickened endometrium. *Asian Pac J Cancer Prev* 2014; 15: 5355-8.

11. Park Y, Vongdala C, Kim J, Ki M. Changing trends in the incidence (1999-2011) and mortality (1983-2013) of cervical cancer in the Republic of Korea. *Epidemiol Health* 2015; 37: e2015024.

12. Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, Lee KH. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. *Cancer Res Treat* 2015; 47: 127-41.

13. Lim MC, Moon EK, Shin A, Jung KW, Won YJ, Seo SS, Kang S, Kim JW, Kim JY, Park SY. Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999–2010. *J Gynecol Oncol* 2013; 24: 298–302.

14. Shin MH, Oh HK, Ahn YO. Ten year trend of cancer incidence in Seoul, Korea: 1993–2002. *J Prev Med Public Health* 2008; 41: 92-9.

15. Berek JS, Novak E. *Berek & Novak’s Gynecology*. 15th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2012.

16. Fritz MA, Speroff L. *Clinical Gynecologic Endocrinology and Infertility*. 8th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2011.

17. Moodley M, Roberts C. Clinical pathway for the evaluation of postmenopausal bleeding with an emphasis on endometrial cancer detection. *J Obstet Gynecol* 2004; 24: 736-41.

18. Dueholm M, Hjorth IM, Secher P, Jørgensen A, Ørtoft G. Reproducibility of endometrial pathologic findings obtained on hysteroscopy, transvaginal sonography, and gel infusion sonography in women with postmenopausal bleeding. *J Minim Invasive Gynecol* 2015; 22: 1636-44.

19. Oh CM, Jung KW, Won YJ, Shin A, Kong HJ, Jun JK, Park SY. Trends in the incidence of in situ and invasive cervical cancer by age group and histological type in Korea from 1993 to 2009. *PLoS One* 2013; 8: e72012.

20. Kyvernitakis I, Kostev K, Hars O, Albert US, Hadji P. Discontinuation rates of menopausal hormone therapy among postmenopausal women in the post-WHI study era. *Climacteric* 2015; 18: 737-42.

21. Kim JY, Sang JH, Park HM. The change of hormone therapy in postmenopausal women in Korea before and after women’s health initiative study: 2000–2009. *Korean J Obstet Gynecol* 2010; 53: 1110-7.

22. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, et al. The effects of tibolone in older postmenopausal women. *N Engl J Med* 2008; 359: 697-708.

23. Hammar ML, van de Weijer P, Franke HR, Pornel B, von Mauw EM, Nijland EA; TOTAL Study Investigators Group. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. *BJOG* 2007; 114: 1522-9.